Independent Research
PRAX Analysis
5 pieces of research on Praxis Precision Medicines, Inc.. We find the signal management buried in the earnings call.
4signal analyses
1news briefs
latest: Oct 20, 2026
Signal Analysis (3)
Analysis
Praxis Jumps on FDA Bets as UBS Targets $706, 171% Upside
Praxis Precision Medicines has a $7.26 billion market cap despite zero revenue, supported by two pending FDA verdicts for ulixacaltamide and relutrigine. UBS ju…
Read analysis →Analysis
PRAX Falls 12% After Trial Setback Following Analyst Boost
Praxis Precision Medicines dropped 12% after-hours following a trial setback, just three days after analysts issued upgrades projecting 91% upside. With no reve…
Read analysis →Analysis
Praxis Jumps on FDA Checks, Vormatrigine Misses Phase 3
Praxis Precision Medicines jumped 15.95% on August 6 after FDA mid-cycle reviews flagged no significant efficacy issues and clinical site inspections returned n…
Read analysis →